Figure 6

The expression of CXCR7 in the presence of α6 and β1 integrin inhibitors. (A) Western blot and densitometric analysis of CXCR7 expression in RWPE1, PC3, HS5 and co-cultured cells (PC3 + HS5). (B) Immunostaining of CXCR7 expression in PC3 cells in the presence of IgG control antibodies and (C) α6 and β1 inhibitors. (D) Immunostaining of CXCR7 expression in HS5 cells. (E-E’) Immunostaining of CXCR7 in co-cultures where HS5 cells (STRO-1) were found to re-express CXCR7 (unfilled arrowheads) at similar levels to that found on PC3 cells (filled arrowhead). (F-F’) In co-cultures, HS5 (STRO-1; unfilled arrowheads) and PC3 cells (Cell Mask; filled arrowheads) continued to express CXCR7 in the presence of α6 inhibitors. (G-G’) In the presence of α6 and β1 inhibitors, HS5 cells (STRO-1; unfilled arrowheads) continued to express CXCR7 at higher levels than found on PC3 cells (filled arrowhead). (H) Western blot and densitometric analysis of CXCR7 expression in HS5 cells using standard, PC3-treated, and 3T3-treated media over a 9 day period. Scale bars = 40 μm.